Cuisinart Food Processor Replacement Parts

The patent ran out?? Pharmaceutical giant and then welcome the test failure

The world’s fourth-largest pharmaceutical company Novartis has announced its 2009 operating results. Filing shows: Novartis in 2009 net Sell Grew 11%, record company history; operating income up 11%; net income rose 4% to 8.5 billion U.S. dollars; basic earnings per share growth of 8% to 4.50 U.S. dollars, higher than 2008′s 3.59 U.S. dollars, for 13 years to achieve growth of shareholder dividend. Novartis said innovation and high performance in 2009, largely thanks to the pharmaceutical sector (patent medicine business) to support double-digit growth performance.

Figures and announced a ten-year results, Novartis, Dr. Pan Jiening Chairman of Greater China, the joy of a smile, it is difficult to realize that the current global pharmaceutical industry is generally facing a dilemma that is now still in the world brand name drug in the history of Drugs The peak time the patent expires, the next 5 years, there will be sales of more than 77 billion U.S. dollars of drug patents about to expire. Including Novartis, including global Pharmaceutical companies Can then easily deal with this dilemma and continue to maintain profit growth?

Patent ran out again Two years ago in March, due to Generic Impact and its patent medicines, “Benzema may” suspend the sales of, Novartis was to enhance the global performance of the overall premise, the results produced in the main area?? U.S. patent drugs business revenue has declined 9%.

This year, the Novartis Group’s two best-selling drugs?? Diovan for the treatment of hypertension and Anti-cancer drugs Gleevec property will face the test of patent expires in 2012.

A long time, Diovan and Gleevec Novartis sales growth has been promoting a major force. In 2008, only Novartis sales in China, sales of Diovan exceeded 500 million U.S. dollars; the other based on January 26 this year, Novartis announced in the fourth quarter 2009 report, generation of text-quarter sales growth of 14% , to 1.6 billion U.S. dollars, annual sales revenue growth of 5%, 60 million; while the same quarter of Gleevec sales rose 22%, to 1.1 billion U.S. dollars, annual sales grew 12% to 3.9 billion.

Diovan and Gleevec the drug has such high sales and annual sales of high-growth, people have worried that once the patent is invalid, the Novartis Group’s results of operations may be affected decline, not to mention, have pointed out the outside world, with the patent expiration date approaches, the Novartis Diovan sales there have been signs of slowing.

Brand drugs face patent is invalid, a situation far more than Novartis, many multinational pharmaceutical giants also fell, therefore performance, and even forced to change strategic direction. Before has the world’s oldest

Pfizer pharmaceutical drugs to compensate for the number one Lipitor patent expiration caused by more than 12 billion U.S. dollars in sales of vacuum, eventually had to conduct a large-scale mergers and acquisitions; later, another top ten global pharmaceutical company Merck, one of the patent has expired for the star to preserve lipid-lowering product “Zocor” sales, price cuts on many occasions, actually at the final bleeding, drop in the Chinese market has more than 50%.

This year, there will be more than Medicine The company’s many drug patents expire, including Merck will lose the next at the end of the treatment of hypertension and Diabetes Best-selling therapeutic effect of losartan in the U.S. market exclusivity; J & J’s broad-spectrum antibiotics levofloxacin patent will expire in December 2010; There is also the company’s leading products Wyeth heartburn drugs?? Pan Pantoprazole, Bayer estradiol hormone replacement therapy agent will expire … …

New product is the last word

“Even if a drug patent expiration of its time in the world is not the same.” Novartis, in response to a reporter about to expire on the impact of two drugs, Panning Jie said that the expiration of drug patents must first correct the misunderstanding.

Then, he himself says, has always been committed to the Novartis Group’s investment in R & D of new drugs, the main purpose is to guarantee that it will continue to introduce new products to meet the supply needs of the market.
About the Author

I am Frbiz Site writer, reports some information about cuisinart 7 cup food processor , food processor oster.


Tagged with: • • • • •

Filed under: Cuisinart Food Processor

Like this post? Subscribe to my RSS feed and get loads more!